Biologics Resources
Find information about our functional bioassays for biologic drug discovery. View scientific presentations and posters with the latest technology and data to help with your research needs.
Join us at these events to learn more about our latest Biologics products and applications:
AACR, April 8–13
PEGS Boston, May 2–6
CASSS Bioassays, July 20–21
Cell Therapy Potency Assay Summit, July 25 - 27
Cytokine-Based Drug Development Summit, July 27 - 28
CAR TCR Summit, Sept 19 - 22
Macrophage-Directed Therapies Summit, Oct 4 -6
Scientific Presentations
Development of Bioluminescent No-wash Fc Gamma Receptor Binding Immunoassay to Guide the Development of Antibody Therapeutics
Presented by Nidhi Nath, Promega Corporation
Quantitative PBMC ADCC Bioassay and ADCC Reporter Bioassays for Immunotherapy and SARS-CoV-2 Monoclonal Antibody Development
Presented by Jeff Nelson, Promega Corporation
HiBiT: A Tiny Tag to Assess MOA-based CAR-T Cell Potency
Presented by Mei Cong, Promega Corporation
MoA-Based Potency Bioassays for Immunotherapy Programs Targeting the TIGIT/CD112R/CD226 Axis
Presented by Kai Hillman, Promega Corporation
Reproducible, MoA-reflecting Reporter-based Bioassays to Enable Discovery and Development of Cytokine Therapeutics
Presented by Vanessa Ott, Promega Corporation
Developing a New HiBiT-PsVLP-based Neutralization Assay Platform for Anti-SARS-CoV-2 Therapy and Beyond
Presented by Jey Cheng, Sr Research Scientist, Promega Corporation
This presentation from BEBPA US 2022 introduces new assays to measure neutralizing activity and Fc effector function for SARS-CoV-2 antibodies. You will learn about:
- A new platform: HiBiT-Pseudotyped Virus-Like Particles (HiBiT- PsVLP)
- Rapid method for measuring neutralizing antibody activity, including in human sera
- Ability to detect differences in antibody neutralization to viral variants
Applying Cell-based Assays to Evaluate the Complex Biology for Drug Candidates Targeting Macrophage -directed Therapies
Presented by Jey Cheng, Sr Research Scientist, Promega Corporation
This presentation supports Macrophage-directed Therapies. You will learn about:
- Measuring the antibody-dependent cellular phagocytosis (ADCP)
- Distinguishing the mechanisms of action between Fc-active or Fc-inactive CD47 antibodies
- Evaluating CD47/SIRPa targeting therapy as monotherapy or combination therapy with antibodies of ADCP MoA
SARS-CoV-2 Bioassays
Presented by Jey Cheng, Sr Research Scientist, Promega Corporation
This presentation introduces bioassays developed to address the two major mechanisms of action for SARS-CoV-2 antibodies. You will learn about:
- The SARS-CoV-2 HiBiT-PsVLP Assay for neutralization activity
- ADCC/ADCP Reporter Bioassays for antibody Fc effector function
Bioluminescent Bioassays: From Reporter Cell Lines to Primary Cells
Presented by Jey Cheng, Sr Research Scientist, Promega Corporation
This presentation introduces our portfolio expansion into primary cell-based assays for immunotherapeutic drug development. You will learn about:
- Using HiBiT-based target cells for ADCC and TDCC assays
- NanoBiT immunoassays for measuring cytokine release
Novel Bioluminescent Bioassays for the Discovery and Development of T Cell Redirecting Cancer Therapies
Presented by Julia Gilden, Sr Research Scientist, Promega Corporation
This presentation will discuss new bioluminescent tools to expedite the development of T cell-redirecting cancer therapies. You will learn about:
- NanoBiT-based assay platforms that can quantitatively measure the potency of CD3 bispecific antibodies or BiTEs to induce T cell-dependent target cell killing and cytokine production.
- TCRαβ-null reporter cell lines that can be used to screen transgenic TCRs against specific tumor antigen targets.
See lists of peer-reviewed publications that used our reporter bioassays for viral vaccine research and immunotherapy drug development assays including mAb therapeutics, bispecific antibodies, oncolytic virus therapy, cancer vaccines, gene therapy and biosimilars.
Scientific Posters
Developing a Bioluminescent PBMC ADCC Assay for the Discovery and Characterization of Therapeutic Antibodies
Presented by Jey Cheng, Sr. Research Scientist
Cell-Based Reporter Bioassays for Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors
Presented by Jamison Grailer, Sr Research Scientist
Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors
Presented by Jamison Grailer, Sr Research Scientist
A No-Wash, Rapid FcRn Binding Immunoassay to Guide the Design and Development of Antibody Therapeutics
Presented by Jeff Nelson, Product Manager
New Products
PBMC ADCC Bioassay
Perform your ADCC method bridging studies with the new PBMC ADCC Bioassay, featuring pre-qualified PBMCs. The assay offers improved consistency and robustness for measuring ADCC. Each assay includes ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. The simple, add-mix-read format uses bioluminescent detection for maximum sensitivity.
Lumit™ Immunoassays
Replace conventional immunoassays, such as Western blots and ELISAs, with new Lumit™ Immunoassays. These assays offer direct luminescence measurement in cell culture, broad dynamic range, and can be completed in as little as 30 minutes.
Lumit™ Immunoassays are available for a range of applications, including protein phosphorylation and pathway analysis, FcRn binding, cytokine detection, metabolite research, and more. You can also build your own Lumit™ immunoassays with our labeling and detection kits.
Learn More
General principle of a Lumit™ Immunoassay. Antibodies are chemically labeled with the small and large subunits of NanoLuc® Luciferase, known as SmBiT and LgBiT, respectively. In the presence of an analyte, the two antibodies come into close proximity, allowing SmBiT and LgBiT to form an active enzyme and generate a bright luminescence signal.
Webinars
Bioanalytical Tools for Biosimilar Development
Learn about functional bioassays and protein characterization reagents to optimize your biosimilar drug development workflow.
Tips and Tools for Successful Immunotherapy Bioassay Development
Our bioassay experts answer your questions about the design, selection and optimization of MOA-based bioassays.
Rapid Antibody Selection Methods for Immunotherapeutic Candidate Development
Learn about time- and cost-saving strategies for selecting antibodies against immunotherapy targets.